ReproCELL Incorporated (TYO:4978)
Japan · Delayed Price · Currency is JPY 212.00
+5.00 (2.42%)
Aug 1, 2025, 3:30 PM JST
CTI BioPharma Revenue
In the fiscal year ending March 31, 2025, ReproCELL had annual revenue of 2.98B JPY with 22.75% growth. ReproCELL had revenue of 910.00M in the quarter ending March 31, 2025, with 40.00% growth.
Revenue
2.98B
Revenue Growth
+22.75%
P/S Ratio
6.74
Revenue / Employee
30.08M
Employees
99
Market Cap
20.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.98B | 552.00M | 22.75% |
| Mar 31, 2024 | 2.43B | -527.00M | -17.85% |
| Mar 31, 2023 | 2.95B | 719.00M | 32.18% |
| Mar 31, 2022 | 2.23B | 948.00M | 73.72% |
| Mar 31, 2021 | 1.29B | 87.00M | 7.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| Daiichi Sankyo Company | 1,886.26B |
| Takeda Pharmaceutical Company | 4,480.25B |
| HOYA Corporation | 866.03B |
| Otsuka Holdings | 2,393.18B |
| Terumo | 1,036.17B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |